Gastric Cancer
Conditions
Interventions
Paclitaxel Liposomes plusTegafur group:Paclitaxel Liposomes +Tegafur
Oxaliplatin plus Tegafur group:Oxaliplatin + Tegafur
Sponsors
the First affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years old male and female; 2. ECOG (Eastern Cooperative Oncology Group) 0-1; 3. Definitely diagnosed gastric adenocarcinoma through Pathology or Cytology; 4. Disease at clinical stage of resectable or potentially resectable(T3-4, N0-3, M0) by CT and endoscopic ultrasonography (EUS); 5. The Expected lifetime =12 weeks; 6. Adequate bone marrow function, defined as: White blood count (WBC)=3.0×10^9/L; Absolute neutrophil count (ANC) =2.0×10^9/L; Platelet count (PLT)=100×10^9/L; Hemoglobin (Hb)=100g/L; 7. Adequate liver function, defined as: Bilirubin =1.5×the upper limit of normal (ULN); Alanine aminotransferase (ALT), or Aspartate aminotransferase (AST) =2.5×(ULN), Alkaline phosphatase(ALP)=5×(ULN); 8. Kidney function defined as: serum creatinine=1.0×(ULN), or endogenous creatinine clearance rate =50 mL/min; 9. Without the history of anti-tumor therapy including Radiotherapy, chemotherapy, targeted therapy, Immunotherapy; 10. Signed the Informed Consent Form.
Exclusion criteria
Exclusion criteria: 1. In the past (5 years) or at the same time with other uncured malignant tumours except for cured skin basal cell carcinoma and cervical carcinoma in situ;With non-removable distant metastasis; 2. With central nervous system metastasis; 3. aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >2.5 times the upper normal limit(ULT); and Alkaline phosphatase(ALP)> 5×(ULN); 4. Previously treated with radiotherapy (pain to palliative radiotherapy and evaluate the lesion was not in the radiation field except); 5. serious uncontrolled co-morbid conditions; 6. Pregnant and lactating women; 7. Patients with reproductive possibilities do not wish or do not take effective contraceptive measures; 8. Simultaneous participation in another study or participation in another study within 4 weeks of commencement of this study; 9. Drug allergy to experimental medicine; 10. The researchers don't think that is suitable for inclusion; 11. Organ allografts requiring immunosuppressive therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DCR; | — |
Secondary
| Measure | Time frame |
|---|---|
| pCR;ORR;Total resection rate;DFS;Safety; | — |
Countries
China
Contacts
Public ContactZhigang Peng
the First affiliated Hospital of Guangxi Medical University
Outcome results
None listed